DK2270172T3 - Kombinationssammensætninger af Neisseria. - Google Patents
Kombinationssammensætninger af Neisseria. Download PDFInfo
- Publication number
- DK2270172T3 DK2270172T3 DK10178238.1T DK10178238T DK2270172T3 DK 2270172 T3 DK2270172 T3 DK 2270172T3 DK 10178238 T DK10178238 T DK 10178238T DK 2270172 T3 DK2270172 T3 DK 2270172T3
- Authority
- DK
- Denmark
- Prior art keywords
- seq
- nos
- sequence
- amino acid
- proteins
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 20
- 241000588653 Neisseria Species 0.000 title claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 61
- 108090000623 proteins and genes Proteins 0.000 claims description 61
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 235000018102 proteins Nutrition 0.000 description 50
- 241000588650 Neisseria meningitidis Species 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 241001212279 Neisseriales Species 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000010912 Transferrin-Binding Proteins Human genes 0.000 description 2
- 108010062476 Transferrin-Binding Proteins Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 101150095079 menB gene Proteins 0.000 description 2
- 229940124731 meningococcal vaccine Drugs 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 1
- 102100024407 Jouberin Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000588677 Neisseria meningitidis serogroup B Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000040340 Oat mosaic virus Species 0.000 description 1
- 102000017033 Porins Human genes 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000037941 meningococcal disease Diseases 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Claims (2)
1. Sammensætning omfattende to eller flere forskellige Neisseria-proteiner, hvor de to eller flere forskellige Neisseria-proteiner omfatter et første protein fra en Neisseria-bakterie og et andet protein fra en Neisseria-bakterie, og hvor (i) det første protein omfatter en aminosyresekvens valgt blandt (a) SEQ ID NO: 2182; (b) en sekvens, der har større end 80% sekvensidentitet med SEQ ID NO: 2182; og det andet protein omfatter en aminosyresekvens valgt blandt (a) én af de lige SEQ ID NOs valgt blandt SEQ ID NOs: 1-2181 og 2183-4002; (b) en sekvens, der har større end 80% sekvensidentitet med én af de lige SEQ ID NOs valgt blandt SEQ ID NOs: 1-2181 og 2183-4002; eller (ii) det første protein omfatter en aminosyresekvens valgt blandt (a) SEQ ID NO: 2184; (b) en sekvens, der har større end 80% sekvensidentitet SEQ ID NO: 2184; og det andet protein omfatter en aminosyresekvens valgt blandt (a) én af de lige SEQ ID NOs valgt blandt SEQ ID NOs: 1-2183 og 2185-4002; (b) en sekvens, der har større end 80% sekvensidentitet med én af de lige SEQ ID NOs valgt blandt SEQ ID NOs: 1-2183 og 2185-4002; eller (iii) det første protein omfatter en aminosyresekvens valgt blandt (a) SEQ ID NO: 2186; (b) en sekvens, der har større end 80% sekvensidentitet med SEQ ID NO: 2186; og det andet protein omfatter en aminosyresekvens valgt blandt (a) én af de lige SEQ ID NOs valgt blandt SEQ ID NOs: 1-2185 og 2187-4002; (b) en sekvens, der har større end 80% sekvensidentitet med én af de lige SEQ ID NOs valgt blandt SEQ ID NOs: 1-2185 og 2187-4002.
2. Sammensætning ifølge krav 1, omfattende to eller flere oprensede proteiner valgt blandt de lige SEQ IDs 1-4002.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9911692.3A GB9911692D0 (en) | 1999-05-19 | 1999-05-19 | Antigenic combinations |
GBGB9919705.5A GB9919705D0 (en) | 1999-08-19 | 1999-08-19 | Antigenic combinations |
GB0005730A GB0005730D0 (en) | 2000-03-09 | 2000-03-09 | Antigenic combinations |
EP07075627A EP1860191A3 (en) | 1999-05-19 | 2000-05-19 | Combination neisserial compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2270172T3 true DK2270172T3 (da) | 2016-02-29 |
Family
ID=27255587
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10178238.1T DK2270172T3 (da) | 1999-05-19 | 2000-05-19 | Kombinationssammensætninger af Neisseria. |
DK10179061.6T DK2270173T3 (da) | 1999-05-19 | 2000-05-19 | Neisseriale kombinationssammensætninger |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10179061.6T DK2270173T3 (da) | 1999-05-19 | 2000-05-19 | Neisseriale kombinationssammensætninger |
Country Status (14)
Country | Link |
---|---|
US (9) | US7862827B2 (da) |
EP (6) | EP2270174A1 (da) |
JP (3) | JP5622344B2 (da) |
CN (2) | CN102580072A (da) |
AU (3) | AU783894B2 (da) |
BR (1) | BR0010721A (da) |
CA (3) | CA2373236C (da) |
CY (2) | CY1117239T1 (da) |
DK (2) | DK2270172T3 (da) |
ES (2) | ES2563650T3 (da) |
MX (1) | MXPA01011867A (da) |
NZ (4) | NZ515935A (da) |
PT (2) | PT2270172E (da) |
WO (1) | WO2000071725A2 (da) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001500738A (ja) | 1996-09-17 | 2001-01-23 | カイロン コーポレイション | 細胞内疾患を処置するための組成物および方法 |
EP2261346A3 (en) * | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
GB9823978D0 (en) * | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
US10967045B2 (en) * | 1998-11-02 | 2021-04-06 | Secretary of State for Health and Social Care | Multicomponent meningococcal vaccine |
EP2278007B1 (en) | 1999-04-30 | 2014-04-16 | Novartis Vaccines and Diagnostics S.r.l. | Conserved neisserial antigens |
CA2373236C (en) * | 1999-05-19 | 2014-08-26 | Chiron S.P.A. | Combination neisserial compositions |
GB9916529D0 (en) * | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
CA2954411A1 (en) | 1999-10-29 | 2001-05-03 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigenic peptides |
GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
DK1947187T5 (da) * | 2000-02-28 | 2011-10-24 | Novartis Vaccines & Diagnostic | Hybrid ekspression af neisserial-proteiner |
AU2004203417B2 (en) * | 2000-05-08 | 2008-02-14 | Microscience Limited | Virulence genes, proteins, and their use |
GB0012079D0 (en) * | 2000-05-18 | 2000-07-12 | Microscience Ltd | Virulence gene and protein, and their use |
GB0020952D0 (en) * | 2000-08-24 | 2000-10-11 | Microscience Ltd | Genes and proteins and their uses |
HU230490B1 (hu) | 2001-01-23 | 2016-08-29 | Sanofi Pasteur Inc. | Multivalens, meningokokkusz-eredetű poliszaccharid és fehérje konjugátumát tartalmazó vakcina |
US7261901B2 (en) | 2001-01-31 | 2007-08-28 | University Of Iowa Research Foundation | Vaccine and compositions for the prevention and treatment of neisserial infections |
WO2002060936A2 (en) * | 2001-01-31 | 2002-08-08 | University Of Iowa Research Foundation | Vaccine and compositions for the prevention and treatment of neisserial infections |
GB0108024D0 (en) | 2001-03-30 | 2001-05-23 | Chiron Spa | Bacterial toxins |
GB0114940D0 (en) * | 2001-06-19 | 2001-08-08 | Chiron Spa | Gene expression during meningococcus adhesion |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
JP4592284B2 (ja) | 2001-07-27 | 2010-12-01 | カイロン ソチエタ ア レスポンサビリタ リミタータ | 髄膜炎菌付着因子 |
GB0121591D0 (en) * | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
AU2012202488B2 (en) * | 2001-09-06 | 2014-01-16 | Glaxosmithkline Biologicals S.A. | Hybrid and tandem expression of Neisserial proteins |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
JP4740738B2 (ja) * | 2002-08-02 | 2011-08-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
CN103007263A (zh) * | 2002-08-02 | 2013-04-03 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗组合物 |
GB0220197D0 (en) * | 2002-08-30 | 2002-10-09 | Univ Utrecht | Refolding method |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
HUE031886T2 (en) | 2002-10-11 | 2017-08-28 | Glaxosmithkline Biologicals Sa | Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines |
ATE466875T1 (de) * | 2002-11-15 | 2010-05-15 | Novartis Vaccines & Diagnostic | Unerwartete oberflächenproteine in neisseria meningitidis |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
GB0315021D0 (en) * | 2003-06-26 | 2003-07-30 | Chiron Srl | Immunogenic gonococcal compositions |
GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
GB0419408D0 (en) * | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
EP1856291A4 (en) * | 2005-03-04 | 2009-04-01 | Verenium Corp | NUCLEIC ACIDS AND PROTEINS, AND METHODS OF MAKING AND USING SAME |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
US20090226479A1 (en) * | 2005-12-23 | 2009-09-10 | Imperial Innovations Limited | Vaccines and their use |
CU23575A1 (es) * | 2006-03-31 | 2010-09-30 | Ct Ingenieria Genetica Biotech | Composición farmacéutica que comprende la proteína nmb0606 |
CU23572A1 (es) * | 2006-03-31 | 2010-09-30 | Ct Ingenieria Genetica Biotech | Composición farmacéutica que comprende la proteína nmb0938 |
EP2044104A2 (en) * | 2006-06-29 | 2009-04-08 | Novartis AG | Polypeptides from neisseria meningitidis |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
AU2009215364B2 (en) * | 2008-02-21 | 2014-09-18 | Glaxosmithkline Biologicals S.A. | Meningococcal fHBP polypeptides |
GB0810742D0 (en) * | 2008-06-12 | 2008-07-16 | Univ Nottingham | Enzyme |
WO2010028246A2 (en) * | 2008-09-05 | 2010-03-11 | Id Biomedical Corporation Of Quebec | Novel compositions and adjuvants |
GB0816447D0 (en) * | 2008-09-08 | 2008-10-15 | Glaxosmithkline Biolog Sa | Vaccine |
IT1394288B1 (it) * | 2008-09-12 | 2012-06-06 | Novartis Vaccines & Diagnostic | Immunogeni di proteine che legano il fattore h. |
DK2411048T3 (da) | 2009-03-24 | 2020-06-15 | Glaxosmithkline Biologicals Sa | Adjuvanterende meningokok-faktor h-bindingsprotein |
BR112012022688A2 (pt) | 2010-03-10 | 2018-05-22 | Glaxosmithkline Biologicals Sa | proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão |
EP2545068B8 (en) * | 2010-03-11 | 2018-03-21 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition or vaccine against gram-negative bacterial, for example neiserial, infection or disease |
CA2803239A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
WO2012012851A1 (en) * | 2010-07-30 | 2012-02-02 | Griffith University | Recombinant neisseria meningitidis por a porin proteins. |
AU2011294776B2 (en) | 2010-08-23 | 2016-02-04 | Wyeth Llc | Stable formulations of Neisseria meningitidis rLP2086 antigens |
GB201014967D0 (en) * | 2010-09-09 | 2010-10-20 | Univ Southampton | Composition |
US9259462B2 (en) | 2010-09-10 | 2016-02-16 | Glaxosmithkline Biologicals Sa | Developments in meningococcal outer membrane vesicles |
GB201015132D0 (en) * | 2010-09-10 | 2010-10-27 | Univ Bristol | Vaccine composition |
CA2809758C (en) | 2010-09-10 | 2021-07-13 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
WO2012059593A1 (en) * | 2010-11-05 | 2012-05-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vaccines for preventing meningococcal infections |
GB201102090D0 (en) * | 2011-02-08 | 2011-03-23 | Univ Sheffield | Antigenic polypeptide |
GB201120634D0 (en) * | 2011-11-30 | 2012-01-11 | Univ Sheffield | Adjuvant polypeptide |
US9657297B2 (en) * | 2012-02-02 | 2017-05-23 | Glaxosmithkline Biologicals Sa | Promoters for increased protein expression in meningococcus |
EP4043029A1 (en) | 2012-03-09 | 2022-08-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
RU2644340C2 (ru) | 2012-06-14 | 2018-02-08 | Новартис Аг | Вакцины для менингококка серогруппы х |
GB201211154D0 (en) * | 2012-06-22 | 2012-08-08 | Univ Southampton | Composition |
AU2013295242C1 (en) | 2012-07-27 | 2018-08-09 | Institut National De La Sante Et De La Recherche Medicale | CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
ES2685894T3 (es) | 2013-03-08 | 2018-10-15 | Pfizer Inc. | Polipéptidos de fusión inmunogénicos |
US9725701B2 (en) | 2013-03-15 | 2017-08-08 | Iowa Corn Promotion Board | Prokarytoic-type isocitrate dehydrogenase and its application for improving nitrogen utilization in transgenic plants |
MX369534B (es) | 2013-09-08 | 2019-11-11 | Pfizer | Composiciones de neisseria meningitidis y sus metodos. |
EP3229835A1 (en) | 2014-12-09 | 2017-10-18 | Sanofi Pasteur | Compositions comprising n. meningitidis proteins |
RU2723045C2 (ru) | 2015-02-19 | 2020-06-08 | Пфайзер Инк. | Композиции neisseria meningitidis и способы их получения |
EP4309670A3 (en) | 2016-09-02 | 2024-07-17 | Sanofi Pasteur, Inc. | Neisseria meningitidis vaccine |
MX2019009011A (es) | 2017-01-31 | 2019-09-26 | Pfizer | Composiciones de neisseria meningitidis y metodos respectivos. |
US20220081707A1 (en) * | 2018-07-25 | 2022-03-17 | The Trustees Of Indiana University | Diagnostic assay for a strain of neisseria meningitidis |
US11618902B2 (en) * | 2020-03-30 | 2023-04-04 | Jiangnan University | Bacillus subtilis for producing N-acetylneuraminic acid and application thereof |
CN111394410B (zh) * | 2020-03-30 | 2022-02-01 | 江南大学 | 一种高催化活性神经氨酸合酶及应用 |
US11579093B2 (en) | 2020-04-22 | 2023-02-14 | SciLogica Corp. | Optical component |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
US4239749A (en) * | 1979-09-27 | 1980-12-16 | United States Of America | Neisseria gonorrhoeae vaccine |
EP0273116A3 (en) | 1986-10-09 | 1990-05-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Gonococcal and meningococcal polypeptides, vaccines and diagnostics |
JPH01125328A (ja) | 1987-07-30 | 1989-05-17 | Centro Natl De Biopreparados | 髄膜炎菌ワクチン |
NL8803111A (nl) * | 1988-12-19 | 1990-07-16 | Nederlanden Staat | Multivalent meningococcen klasse i buitenmembraaneiwit vaccin. |
IE912559A1 (en) | 1990-07-19 | 1992-01-29 | Merck & Co Inc | The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same |
DE69227898T2 (de) | 1991-03-14 | 1999-05-12 | Imclone Systems, Inc., New York, N.Y. | Rekombinante hybride porinepitope |
FR2692592B1 (fr) | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant. |
DK0624376T3 (da) | 1993-05-13 | 2000-07-24 | American Cyanamid Co | Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci |
US5439808A (en) | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
ATE173634T1 (de) | 1994-04-20 | 1998-12-15 | Us Army | Impfstoff gegen gram-negative bakterielle infektionen |
FR2720408B1 (fr) | 1994-05-31 | 1996-08-14 | Pasteur Merieux Serums Vacc | Fragments Tbp2 de Neisseria meningitidis. |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
US6180111B1 (en) | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
EA199800208A1 (ru) * | 1995-09-18 | 1998-10-29 | Юнайтед Стэйтс Арми Медикал Ресерч Материэл Комманд (Юсамрмк) | Усовершенствованные способы изготовления нековалентно комплексированных и поливалентных вакцин протеосомной подгруппы |
FR2739624B1 (fr) | 1995-10-10 | 1997-12-05 | Pasteur Merieux Serums Vacc | Nouvelle sous-unite tbp2 de neisseria meningitidis |
AU2115897A (en) * | 1996-02-01 | 1997-08-22 | North American Vaccine, Inc. | Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines |
AU5426098A (en) | 1996-10-24 | 1998-05-15 | Emory University | Invasion associated genes from (neisseria meningitidis) serogroup |
DE69737125T3 (de) | 1996-10-31 | 2015-02-26 | Human Genome Sciences, Inc. | Streptococcus pneumoniae-Antigene und Impfstoffe |
JP2001510169A (ja) | 1997-07-17 | 2001-07-31 | ノース アメリカン ワクチン, インコーポレイテッド | B型髄膜炎菌性ポーリンおよびH.influenzae多糖体を含む免疫原性結合体 |
BR9811907A (pt) * | 1997-08-15 | 2000-08-15 | Univ Utrecht | Proteìna de ligação de lactoferrina de neisseria |
US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
CA2308606A1 (en) * | 1997-11-06 | 1999-05-20 | Chiron S.P.A. | Neisserial antigens |
GB9726398D0 (en) * | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
PT1047784E (pt) * | 1998-01-14 | 2009-12-21 | Novartis Vaccines & Diagnostic | Antigénios de neisseria meningitidis |
GB9808866D0 (en) | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
EP2261346A3 (en) * | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
US20070026021A1 (en) | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
AT2941U1 (de) | 1998-05-06 | 1999-07-26 | Fleischhacker Gerhard | Flexible flüssigkeitssperre |
EP1741443B1 (en) | 1998-05-29 | 2014-05-21 | Novartis Vaccines and Diagnostics, Inc. | Combination meningitidis B/C vaccines |
JP5074644B2 (ja) | 1998-05-29 | 2012-11-14 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 組合わせの髄膜炎菌b/cワクチン |
US6248329B1 (en) | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
MXPA01003557A (es) * | 1998-10-09 | 2004-04-05 | Chiron Corp | Secuencias genomicas de neisseria y metodos para su uso. |
GB9823978D0 (en) * | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
US20030215469A1 (en) | 1998-11-02 | 2003-11-20 | Microbiological Research Authority | Multicomponent meningococcal vaccine |
CA2371994C (en) * | 1999-02-26 | 2010-09-28 | Guido Grandi | Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs |
CN1359426A (zh) | 1999-04-30 | 2002-07-17 | 希龙公司 | 奈瑟球菌基因组序列及其用法 |
EP2278007B1 (en) | 1999-04-30 | 2014-04-16 | Novartis Vaccines and Diagnostics S.r.l. | Conserved neisserial antigens |
CA2373236C (en) | 1999-05-19 | 2014-08-26 | Chiron S.P.A. | Combination neisserial compositions |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
CA2954411A1 (en) | 1999-10-29 | 2001-05-03 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigenic peptides |
AU1917501A (en) | 1999-11-12 | 2001-06-06 | University Of Iowa Research Foundation, The | Control of neisserial membrane synthesis |
DK1897555T3 (da) | 2000-01-17 | 2014-10-13 | Novartis Vaccines & Diagnostic | Kompletteret OMV-vaccine mod meningococcus |
BR0107857A (pt) | 2000-01-25 | 2002-10-29 | Univ Queensland | Proteìnas compreendendo regiões conservadas de antìgeno nhha de superfìcie de neisseria meningitidis |
DK1947187T5 (da) | 2000-02-28 | 2011-10-24 | Novartis Vaccines & Diagnostic | Hybrid ekspression af neisserial-proteiner |
NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
US6936261B2 (en) | 2000-07-27 | 2005-08-30 | Children's Hospital & Research Center At Oakland | Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
GB0103424D0 (en) * | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
AU2002252638A1 (en) | 2001-04-17 | 2002-10-28 | Children's Hospital Oakland Research Institute | Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
CN100350972C (zh) | 2001-07-26 | 2007-11-28 | 启龙股份公司 | 含有铝佐剂和组氨酸的疫苗 |
JP4592284B2 (ja) * | 2001-07-27 | 2010-12-01 | カイロン ソチエタ ア レスポンサビリタ リミタータ | 髄膜炎菌付着因子 |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0130123D0 (en) | 2001-12-17 | 2002-02-06 | Microbiological Res Agency | Outer membrane vesicle vaccine and its preparation |
JP4740738B2 (ja) | 2002-08-02 | 2011-08-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
HUE031886T2 (en) | 2002-10-11 | 2017-08-28 | Glaxosmithkline Biologicals Sa | Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines |
ATE466875T1 (de) | 2002-11-15 | 2010-05-15 | Novartis Vaccines & Diagnostic | Unerwartete oberflächenproteine in neisseria meningitidis |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
WO2004054611A1 (en) | 2002-12-16 | 2004-07-01 | Nasjonalt Folkehelseinstitutt | Meningococcal vaccine based on outer membrane proteins porb2 and pora |
EP1590459A2 (en) | 2003-01-15 | 2005-11-02 | Wyeth Holdings Corporation | Methods for increasing neisseria protein expression and compositions thereof |
CA2514328C (en) | 2003-01-30 | 2020-01-14 | Chiron Srl | Injectable vaccines against multiple meningococcal serogroups |
US20070253964A1 (en) | 2003-04-16 | 2007-11-01 | Zlotnick Gary W | Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease |
GB0315021D0 (en) | 2003-06-26 | 2003-07-30 | Chiron Srl | Immunogenic gonococcal compositions |
GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
EP1670506B1 (en) | 2003-10-02 | 2012-11-21 | Novartis AG | Liquid vaccines for multiple meningococcal serogroups |
US7628995B2 (en) | 2003-12-23 | 2009-12-08 | Glaxosmithkline Biologicals S.A. | Outer membrane vesicles and uses thereof |
GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
GB0409748D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Lactoferrin cleavage |
GB0419408D0 (en) | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
AU2006208208B2 (en) | 2005-01-27 | 2011-05-19 | Children's Hospital & Research Center At Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
WO2008001244A2 (en) | 2006-06-23 | 2008-01-03 | Harun Aksoy | A stone |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
WO2008125985A2 (en) | 2007-04-11 | 2008-10-23 | Novartis Ag | Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes |
CA2688268A1 (en) | 2007-06-04 | 2008-12-11 | Novartis Ag | Formulation of meningitis vaccines |
US20090035328A1 (en) | 2007-08-02 | 2009-02-05 | Dan Granoff | fHbp- AND LPXL1-BASED VESICLE VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS |
AU2009215364B2 (en) | 2008-02-21 | 2014-09-18 | Glaxosmithkline Biologicals S.A. | Meningococcal fHBP polypeptides |
CA2717870A1 (en) | 2008-03-10 | 2009-09-17 | Children's Hospital & Research Center At Oakland | Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use |
NZ589812A (en) | 2008-05-30 | 2012-08-31 | U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Inst Of Res | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
US8470340B2 (en) | 2008-09-03 | 2013-06-25 | Children's Hospital & Research Center Oakland | Peptides presenting an epitope of a domain of factor H binding protein and methods of use |
GB0816284D0 (en) | 2008-09-05 | 2008-10-15 | Nat Biolog Standards Board | Vaccine |
IT1394288B1 (it) | 2008-09-12 | 2012-06-06 | Novartis Vaccines & Diagnostic | Immunogeni di proteine che legano il fattore h. |
GB0819633D0 (en) | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
US20120064104A1 (en) | 2009-03-24 | 2012-03-15 | Novartis Ag | Combinations including pneumococcal serotype 14 saccharide |
DK2411048T3 (da) | 2009-03-24 | 2020-06-15 | Glaxosmithkline Biologicals Sa | Adjuvanterende meningokok-faktor h-bindingsprotein |
BR112012022688A2 (pt) | 2010-03-10 | 2018-05-22 | Glaxosmithkline Biologicals Sa | proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão |
ES2661569T3 (es) | 2010-03-30 | 2018-04-02 | Children's Hospital & Research Center At Oakland | Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas |
US9427476B2 (en) | 2012-05-24 | 2016-08-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Multivalent meningococcal conjugates and methods for preparing conjugates |
-
2000
- 2000-05-19 CA CA2373236A patent/CA2373236C/en not_active Expired - Fee Related
- 2000-05-19 EP EP10179491A patent/EP2270174A1/en not_active Withdrawn
- 2000-05-19 ES ES10178238.1T patent/ES2563650T3/es not_active Expired - Lifetime
- 2000-05-19 PT PT101782381T patent/PT2270172E/pt unknown
- 2000-05-19 ES ES10179061.6T patent/ES2563677T3/es not_active Expired - Lifetime
- 2000-05-19 CA CA2929348A patent/CA2929348A1/en not_active Abandoned
- 2000-05-19 WO PCT/IB2000/000828 patent/WO2000071725A2/en active IP Right Grant
- 2000-05-19 NZ NZ515935A patent/NZ515935A/xx not_active IP Right Cessation
- 2000-05-19 CN CN2011104630251A patent/CN102580072A/zh active Pending
- 2000-05-19 PT PT101790616T patent/PT2270173E/pt unknown
- 2000-05-19 DK DK10178238.1T patent/DK2270172T3/da active
- 2000-05-19 NZ NZ545647A patent/NZ545647A/en not_active IP Right Cessation
- 2000-05-19 EP EP07075627A patent/EP1860191A3/en not_active Withdrawn
- 2000-05-19 NZ NZ536676A patent/NZ536676A/en not_active IP Right Cessation
- 2000-05-19 EP EP10178238.1A patent/EP2270172B1/en not_active Expired - Lifetime
- 2000-05-19 EP EP10179168A patent/EP2258851A1/en not_active Withdrawn
- 2000-05-19 BR BR0010721-2A patent/BR0010721A/pt not_active IP Right Cessation
- 2000-05-19 EP EP00935438A patent/EP1179072A2/en not_active Ceased
- 2000-05-19 CA CA2838395A patent/CA2838395C/en not_active Expired - Fee Related
- 2000-05-19 CN CNB008106002A patent/CN100338218C/zh not_active Expired - Fee Related
- 2000-05-19 AU AU50977/00A patent/AU783894B2/en not_active Ceased
- 2000-05-19 DK DK10179061.6T patent/DK2270173T3/da active
- 2000-05-19 MX MXPA01011867A patent/MXPA01011867A/es active IP Right Grant
- 2000-05-19 EP EP10179061.6A patent/EP2270173B1/en not_active Expired - Lifetime
- 2000-05-19 JP JP2000620102A patent/JP5622344B2/ja not_active Expired - Fee Related
- 2000-05-19 NZ NZ528254A patent/NZ528254A/en not_active IP Right Cessation
-
2004
- 2004-11-05 US US10/982,703 patent/US7862827B2/en not_active Expired - Fee Related
- 2004-11-09 US US10/984,376 patent/US20050244436A1/en not_active Abandoned
-
2006
- 2006-03-20 AU AU2006201153A patent/AU2006201153B2/en not_active Ceased
-
2007
- 2007-05-24 JP JP2007138403A patent/JP2007224047A/ja active Pending
-
2009
- 2009-02-27 AU AU2009200865A patent/AU2009200865B2/en not_active Ceased
-
2010
- 2010-12-27 US US12/979,239 patent/US20110104193A1/en not_active Abandoned
-
2012
- 2012-02-03 US US13/366,226 patent/US20120135026A1/en not_active Abandoned
- 2012-11-22 JP JP2012256105A patent/JP2013047274A/ja active Pending
-
2013
- 2013-06-18 US US13/921,087 patent/US20140037668A1/en not_active Abandoned
-
2014
- 2014-05-21 US US14/284,326 patent/US20150174231A1/en not_active Abandoned
-
2016
- 2016-02-03 US US15/015,004 patent/US9610342B2/en not_active Expired - Fee Related
- 2016-02-03 US US15/015,041 patent/US9364528B1/en not_active Expired - Fee Related
- 2016-03-01 CY CY20161100175T patent/CY1117239T1/el unknown
- 2016-03-01 CY CY20161100173T patent/CY1117235T1/el unknown
-
2017
- 2017-02-21 US US15/438,584 patent/US20170165346A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2270172T3 (da) | Kombinationssammensætninger af Neisseria. | |
JP7555785B2 (ja) | 改変髄膜炎菌fHbpポリペプチド | |
US11708394B2 (en) | Modified meningococcal FHBP polypeptides | |
JP5564297B2 (ja) | 髄膜炎菌タンパク質nmb1870の複数の改変体 | |
Christodoulides et al. | Novel approaches to Neisseria meningitidis vaccine design | |
Masignani et al. | Reverse vaccinology: a genome-based approach for vaccine development | |
JP2005531614A (ja) | ワクチン組成物 | |
Holst | Strategies for development of universal vaccines against meningococcal serogroup B disease | |
EA038940B1 (ru) | Менингококковые вакцины | |
Williams et al. | Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens | |
ES2351598T3 (es) | Proteína frpb mutante y procedimiento de replegamiento. | |
AU2016228231A1 (en) | Combination Neisserial compositions | |
RU2244749C2 (ru) | Композиция для лечения или профилактики инфекции, вызванной бактерией neisseria | |
Kaaijk et al. | Routine vaccination against MenB | |
Serino et al. | Meningococcal diseases: From genomes to vaccines | |
Lattanzi et al. | Novel vaccination strategies |